STOCK TITAN

Milestone Pharmaceuticals: 10.1% passive stake reported

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. (MIST) is the issuer named in an amended ownership report listing 12,615,010 common shares, or 10.1%, as beneficially owned by each of four reporting persons: Propel Bio Management, LLC, Leen Kawas, Richard Kayne and Propel Bio Partners LLC. The repeated amounts reflect shared attribution rather than four distinct blocks: the report says 9,615,010 shares are held by investment funds and an investment company advised by Propel and Kawas, and 3,000,000 by the Richard and Suzanne Kayne Living Trust, of which Kayne is trustee. The report includes express disclaimers of beneficial ownership and group status. The percentage calculation uses 124,498,693 common shares outstanding as of November 13, 2026.

Reported beneficial ownership 12,615,010 shares Reported for each of the four reporting persons
Percentage of class 10.1% Reported for each reporting person
Shares held by advised funds 9,615,010 shares Directly owned by private investment funds and an investment company for which Propel Bio Management, LLC and Leen Kawas provide discretionary advisory services
Shares held by family trust 3,000,000 shares Directly owned by the Richard and Suzanne Kayne Living Trust
Common shares outstanding 124,498,693 shares As of November 13, 2026; used for the ownership calculation
beneficial ownership regulatory
"The beneficial ownership of the securities reported herein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 13d-3 regulatory
"for purposes of Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
Rule 13d-4 regulatory
"In accordance with Rule 13d-4"
discretionary advisory services financial
"provide discretionary advisory services"
sole dispositive power regulatory
"Sole Dispositive Power 12,615,010.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Company Act of 1940 regulatory
"registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MIST shares are reported as beneficially owned?

Each of the four reporting persons is listed for 12,615,010 common shares, or 10.1% of the class; the entries reflect shared attribution of the reported holdings, not four separate blocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





59935V107

(CUSIP Number)
11/19/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G. (2) Calculations are based on 124,498,693 common shares outstanding as of November 13, 2026, as disclosed by the Issuer on its Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G. (2) Calculations are based on 124,498,693 common shares outstanding as of November 13, 2026, as disclosed by the Issuer on its Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G. (2) Calculations are based on 124,498,693 common shares outstanding as of November 13, 2026, as disclosed by the Issuer on its Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G. (2) Calculations are based on 124,498,693 common shares outstanding as of November 13, 2026, as disclosed by the Issuer on its Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026.


SCHEDULE 13G



Propel Bio Management, LLC
Signature:Leen Kawas
Name/Title:Managing Member
Date:11/20/2026
Leen Kawas
Signature:Leen Kawas
Name/Title:Individual
Date:11/20/2026
Richard Kayne
Signature:Richard Kayne
Name/Title:Individual
Date:11/20/2026
Propel Bio Partners LLC
Signature:Leen Kawas
Name/Title:Managing Member
Date:11/20/2026

Keep reading